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Abstract
Background: Metastatic breast cancer (MBC) remains incurable despite significant treatment advances. Coordinating care for
patients with MBC can be challenging given the various treatment options, available clinical trials, and frequent need for ancillary
services. To optimize MBC care, we designed a project for adapting and developing an academic and community practice
collaborative care model for MBC care (Project ADAPT), based on the Ending Metastatic Breast Cancer for Everyone (EMBRACE)
program developed at Dana Farber Cancer Institute.
Objective: We aim to describe the implementation science–based study design and innovative components of Project ADAPT.
Methods: Project ADAPT uses the Dynamic Adaptation Process informed by the Exploration, Preparation, Implementation,
Sustainment framework. Washington University School of Medicine (WUSM) partnered with 3 community hospitals in the St.
Louis region covering rural and urban settings. The exploration and preparation phases provide patient and provider feedback on
current referral practices to finalize the approach for the implementation phase. At the implementation phase, we will enroll
patients with MBC at these 3 community sites to evaluate potential collaborative care at WUSM and assess the impact of this
collaborative care model on referral satisfaction and acceptability for patients with MBC and their providers. Patients may then
return to their community site for care or continue to receive part of their care at WUSM. We are incorporating virtual and digital
health strategies to improve MBC care coordination in order to minimize patient burden.
Results: The exploration phase is ongoing. As of August 2021, we have recruited 21 patient and provider participants to complete
surveys of the current collaborative care process at WUSM. Using a 2-tailed paired t test, 44 patients (including 10 patients from
the exploration phase) and 32 oncologists are required to detect an effect size of 0.5 with 80% power at a level of significance of
.05. Throughout this phase and in preparation for the implementation phase, we have iteratively updated and refined our surveys
for the implementation phase based on testing of our data collection instruments. Our partner sites are in various stages of the
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single institutional review board (IRB) approval process. We have ongoing engagement with all partner sites, which has helped
solidify our participant recruitment strategies and design patient-friendly recruitment materials. In addition, we have included a
patient advocate on the research team. Members of the research team have launched a single IRB Support Network at WUSM to
create a repository of the single IRB procedures in order to streamline the partner site onboarding process and facilitate enhanced
collaboration across institutions.
Conclusions: With this robust model, we expect that patients with MBC will receive optimal care regardless of geographical
location and the model will improve patient and provider experiences when navigating the health system.
International Registered Report Identifier (IRRID): DERR1-10.2196/35736
(JMIR Res Protoc 2022;11(7):e35736) doi: 10.2196/35736
KEYWORDS
metastatic breast cancer; care coordination; Project ADAPT; referral process; implementation science; oncology; community
practice; academic institutions; breast cancer; cancer; breast; implementation; science

Introduction
Background
As of 2019, there were over 3.8 million breast cancer survivors
in the United States, with this number projected to increase
substantially by 2030 [1]. Excluding skin cancers, breast cancer
is the most common cancer type and accounts for 30% of new
cancer diagnoses in the United States [2,3]. In 2021, breast
cancer incidence was expected to be 284,200 in the United
States, with a 0.5% annual increase [3]. Although mortality
rates have declined, the projected number of deaths from breast
cancer in 2021 was over 44,000, and nearly all these deaths
were due to metastatic breast cancer (MBC), which has a median
survival of about 3 years [3,4]. Breast cancer incidence is higher
in urban populations than among those living in rural settings
[5]. However, this rural-urban disparity has been attributed to
lower mammography screening rates, due to limited access to
health care services in rural settings and low socioeconomic
status [6,7], impacting this population’s ability to obtain quality
care and making the diagnosis of breast cancer at later stages
more likely [8]. When viewed at the population level, these
barriers often explain the observed gap in breast cancer
incidence between urban and rural populations [7].
Despite significant advances in treatment, there is no cure for
MBC [9-12]. Current treatment options are palliative in nature
with the goal of extending survival and improving quality of
life, but are frequently encumbered by care coordination
challenges [9,11,13]. Even with national guidelines for the
treatment of MBC and subtype-specific MBC, which encourage
participation in clinical trials [14-16], there is not always a clear
sequence of treatments or an accessible clinical trial available
for patients, particularly those in rural settings [9,17-19].
Additionally, there is often a need for ancillary supportive care
services for patients with MBC [17,19]. The complexities
involved in the routine care of patients with MBC can lead to
underutilization or overutilization of care; missed opportunities
to improve cancer outcomes, including cancer-specific survival
and treatment-related symptoms; and undue patient and care
delivery burden. Therefore, there is a need for coordinated care
models that cater to the increasing prevalence of patients with
MBC in the United States [20].
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Limitations of Current Care Models
Patients with MBC usually choose to receive cancer care near
their homes. Treatment may be at a community or academic
center. However, while many patients live near academic
centers, a considerable number of patients also travel to
academic centers for treatment or second opinions, clinical trial
options, and ancillary services not available at their local
community practice [21]. Effective coordination and
communication between the referring provider and oncologists
at academic centers are needed to maximize the benefits of these
consultations. When coordination is lacking, patients may be
seen at an academic center when they are not candidates for a
clinical trial or when a relevant trial is unavailable. Treatment
plans may also be delayed if certain medical records or
up-to-date test results are unavailable. In addition, patients are
often not referred due to referring physicians’ lack of access to
real-time clinical trial options at an academic cancer center or
their concern for patient burden, including financial
responsibility, health insurance limitations, and transportation
cost [17,19,22]. Given these referral barriers, communication
is often limited to a phone call or email between individual
physicians, which is not always a secure, reliable, or organized
approach. This way of communication also inhibits collaborative
consultations for patients who may benefit from a
multidisciplinary review of their case. Therefore, existing
communication media and channels lack efficiency and create
barriers to eliciting a second opinion or screening patients
potentially eligible for clinical trials. Ultimately, a lack of
consistent uniform coordination and communication among
physicians is likely to result in decreased patient satisfaction
and potentially missed opportunities to improve patient
outcomes [13].
Addressing physician-level barriers to referring patients, such
as physicians’ lack of awareness of available trials, concern of
losing patients, and lack of time [23], is imperative to adequate
patient care. Additionally, current referral practices
encompassing preappointment communication regarding
available trials, required testing and records, patient functional
status, and preferences must be honed among academic and
referring community centers. A collaborative care model can
improve workflow, minimize patient burden, improve care
delivery and communication between physicians, and ultimately
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enhance the referral process between academic and community
cancer centers [22].
In this protocol paper, we describe the implementation science
study design of a project for adapting and developing an
academic and community practice collaborative care model for
MBC care (Project ADAPT). This project evaluates clinical
health service utilization (eg, access and utilization of clinical
trials, virtual consult/telemedicine, and genomic testing), and
the fidelity and adoption of a coordinated care intervention
between academic and community settings. This model can
then be tested on a larger scale, with a more significant number
of community partners, to evaluate its impact on additional
outcomes, including quality of life, and progression-free and
overall survival, among patients with MBC.

Methods
Study Development
EMBRACE Program
Project ADAPT originated from a review of the Ending
Metastatic Breast Cancer for Everyone (EMBRACE) clinical
program at the Dana Farber Cancer Institute (DFCI) [24]. The
DFCI research team explicitly designed the EMBRACE program
for MBC to (1) enhance the longitudinal care of patients with
MBC; (2) develop a robust, seamless, collaborative care model
between the DFCI and referring providers; and (3) improve the
quality of life and satisfaction with care among patients with
MBC. To accomplish these goals, EMBRACE created a clinical
flow model that identifies patients with MBC seen at the DFCI
(either newly diagnosed or recently seen at the DFCI),
streamlines and coordinates the initial consultation, facilitates
treatment at the DFCI or collaborative care between institutions,
and coordinates reconsultations at the DFCI on disease
progression. This process enables ongoing contact with the
patient and between providers, and leverages the expertise of
providers and health care administrators to achieve this care
coordination for MBC [24].
Most medical oncologists at the DFCI who completed the initial
baseline survey reported moderate satisfaction with the initial
consultation and stated that access to the referring provider’s
email was extremely important. They expressed dissatisfaction
with the current approach of accessing the emails of referring
providers. In addition, among referring providers, most reported
difficulty in referring patients to academic institutions for
clinical trials. Patients who completed the baseline survey at
the DFCI strongly desired all aspects of information on their
cancer and treatment [24].
With similar challenges in our local institution and community,
and with this intervention in mind, we adapted existing
knowledge and tools from EMBRACE into the design and
implementation of a care model for the patients, providers, and
local community cancer sites in and around St. Louis, Missouri
by engaging several community practices and experts in
implementation science and medical oncology. We named this
intervention Project ADAPT.

https://www.researchprotocols.org/2022/7/e35736

XSL• FO
RenderX

Housten et al

Project ADAPT
Disparities in breast cancer stage at diagnosis have been
observed in the St. Louis region among medically underserved
patients and have been attributed to barriers in the referral
pathway to Siteman Cancer Center (SCC), the only National
Cancer Institute (NCI)-designated comprehensive cancer center
within a 240-mile radius of St. Louis [25]. SCC comprises
physicians and researchers from Washington University School
of Medicine (WUSM), Barnes-Jewish Hospital, and St. Louis
Children’s Hospital. Thus, SCC provides several vital resources
for cancer research in the St. Louis metropolitan area and
extends throughout the catchment area. Approximately
10%-15% of patients referred via private health care practices
presented at late stages (stages III and IV) compared with about
40% of patients referred via Safety Net clinics, a referral system
used by community clinics that cater primarily to uninsured and
underinsured locals [25]. A collaborative care model has the
potential to address these disparities. Existing collaborative care
challenges identified by the research team include the need for
(1) efficient and reliable communication between the referring
community and accepting academic providers; (2) optimal
timing of genomic testing to aid in decision-making for next-line
therapies and access to clinical trials; and (3) minimizing patient
burden (eg, excess travel and unnecessary in-person
appointments).
The goal of Project ADAPT is to implement a multilevel
collaborative model between academic and referring community
oncology practices to accelerate the translation of evidence into
practice to improve MBC management and the patient referral
process. This multilevel model for coordinated care leverages
the clinical expertise of oncologists at both the academic and
partner institutions managing patients with MBC, the numerous
clinical trials available at SCC, and the unique NCI Community
Oncology Research Program (NCORP) resources at the
community partner centers. Employing the single institutional
review board (IRB) structure through the WUSM, Project
ADAPT extends existing SCC partnerships in the St. Louis
region to develop a sustainable collaborative care model [26].
To achieve this goal, we have the following specific objectives:
(1) assess patients’ satisfaction and acceptability of the academic
and community collaborative care model for their MBC care;
(2) evaluate providers’ (academic oncologists and referring
oncology providers) satisfaction and acceptability of the
collaborative care model with the referral and management
processes of MBC patients; and (3) evaluate the implementation
of the adapted EMBRACE program using fidelity and adoption
measures.
To accelerate the translation of evidence-informed MBC
management across multiple systems into practice, we are using
the dynamic adaptation process (DAP) to adapt EMBRACE to
reflect the characteristics and context of the St. Louis regional
care environment [27,28]. This approach builds upon the
EMBRACE evidence-informed practice and modifies the
intervention to fit the proposed collaborative environment of
St. Louis. This adaptation includes the 4-phase Exploration,
Preparation, Implementation, Sustainment (EPIS) model for
multilevel program design [27,28]. This innovative
implementation science framework allows us to assess our
JMIR Res Protoc 2022 | vol. 11 | iss. 7 | e35736 | p. 3
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multilevel strategy by incorporating ongoing feedback to make
modifications during the investigation, thereby enhancing our
ability to intervene by identifying and testing real-time
developments as needed to advance the pace of translating
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evidence into practice. Figure 1 shows the theoretical pathway
of Project ADAPT using the DAP and EPIS implementation
science framework [27,28].

Figure 1. Research strategy. Figure adapted from the Dynamic Adaptation Process and Exploration, Preparation, Implementation, Sustainment
framework. EMBRACE: Ending Metastatic Breast Cancer for Everyone; Project ADAPT: project for adapting and developing an academic and
community practice collaborative care model for metastatic breast cancer care; MBC: metastatic breast cancer; WUSM: Washington University School
of Medicine.

Ethics Approval
WUSM/SCC received single IRB approval in May 2021 from
the Washington University Institutional Review Board (Protocol
#202104173-1001). Due to the various characteristics of our 3
partner sites, these sites are in different stages in the
administrative and registration processes to obtain single IRB
approval through the WUSM IRB. Utilizing the single IRB
approval process strengthens the existing executive partnerships
to create a sustainable research collaboration [26].

Study Settings
Washington University in St. Louis School of Medicine
(WUSM) is partnering with the following 3 community hospitals
within the St. Louis region to establish this care model: Missouri
Baptist Medical Center (MBMC) in St. Louis County, Missouri;
Southern Illinois Healthcare (SIH) in Carbondale, Illinois; and
Phelps Health Delbert Day Cancer Institute (DDCI) in Rolla,
Missouri. These hospitals are affiliated with broader regional
health care organizations that offer the potential to expand and
scale-up Project ADAPT. An existing informal referral
relationship exists between each of these partner sites and SCC.
Therefore, we are building off this foundational relationship to
coordinate care for patients with MBC. Specifically, MBMC
and SIH are affiliated with The BJC Collaborative, LLC, an
https://www.researchprotocols.org/2022/7/e35736
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organization inclusive of 7 health systems in Missouri and
Illinois working together to enhance the quality of care, increase
access to health services through meaningful population health
benefits, and reduce the total cost of care within the Midwest
region. Phelps Health is a county hospital serving South Central
Missouri, whose Delbert Day Cancer Institute is affiliated with
the Siteman Cancer Network, an affiliation led by SCC
committed to improving the health and well-being of people
and communities through research, treatment, and prevention.
WUSM is the project’s lead/coordinating site.
The lead site, WUSM, has an extensive history of research,
education, and patient care, as one of the preeminent medical
research institutions in the United States. SCC is the only
NCI-designated cancer center in Missouri and is part of the
main Washington University Medical Center campus with
multiple satellite locations throughout the St. Louis region. SCC
brings together over 450 physicians and researchers from
WUSM, Barnes-Jewish Hospital, and St. Louis Children’s
Hospital (both part of BJC Healthcare). Thus, SCC provides
several vital resources for cancer research in the St. Louis area,
with extension throughout the SCC catchment area.
MBMC’s Cancer Center is a regional leader in providing care
and support to patients throughout their cancer care. This cancer
center aims to deliver treatment, comprehensive care, and
JMIR Res Protoc 2022 | vol. 11 | iss. 7 | e35736 | p. 4
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advanced research to patients receiving care in the surrounding
areas. The hospital has over 1700 new cancer cases each year,
and the cancer center is staffed with 8 medical oncologists.
MBMC has outreach sites in more rural areas in Missouri and
Illinois, for example, MoBap Sullivan in Sullivan, Missouri,
and is an active partner in this effort to share best practices and
recruit women with MBC. In 2019, prior to the COVID-19
pandemic (as this has caused significant disruptions in cancer
care), MBMC’s Cancer Center referred 3 out of 41 patients with
MBC to SCC.
SIH is a leading health care system serving the people of
southern Illinois. SIH offers services in rural clinics in addition
to a regional referral center for the 16-county region. SIH aims
to provide expertise and advanced treatments tailored for the
needs of the rural setting. As the region’s first dedicated cancer
treatment center, the SIH Cancer Institute provides surgical and
treatment options using evidence-based approaches to advance
the care of patients with MBC. There are 5 medical oncologists,
2 radiation oncologists, and 1 breast surgical oncologist in the
cancer program serving an estimated 200 breast cancer patients
yearly. From 2016 to early 2019, out of the 26 patients with
MBC seen at SIH, there were no referrals to SCC.
The DDCI provides cancer care services and continuity of care
for patients in a rural 7-county region across South Central
Missouri. The DDCI offers radiotherapy, medical oncology,
laboratory, clinical research, and imaging services. All cancer
treatment and support services are at a single location to ensure
the best possible patient experience and to ease the burden of
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traveling to multiple locations for treatment. In addition, it offers
ancillary services, such as patient education and customized
counseling services, to achieve the mission to improve the health
and wellness of people in the region. The Phelps Health DDCI
had 10 patients with MBC, with only 1 referral made to SCC,
in 2019.

Study Population
In the exploration phase, participants must meet the following
inclusion criteria: (1) diagnosis of MBC (stage IV); (2) referral
to SCC for MBC treatment; and (3) referral before the
implementation phase of Project ADAPT. For the
implementation phase, the inclusion criteria are (1) histologically
or cytologically confirmed MBC (this includes newly diagnosed
[de novo] or recurrent metastatic disease); (2) age ≥18 years;
(3) self-reported ability to speak and understand English; and
(4) willingness to provide written informed consent. There are
no participant limitations based on sex.
For this protocol paper, providers recruited for this study are
oncologists who primarily manage MBC cases and are involved
in the referral process of patients with MBC. We have used the
term “provider” throughout the protocol to make it inclusive
for other sites that may replicate this study and have clinical
buy-in from a variety of health care providers. The inclusion
criteria for oncologists are as follows: (1) academic oncologists
from SCC and oncologists from participating partner community
sites, and (2) willingness to provide written informed consent.
Table 1 shows the distribution of participants throughout the
study phases.

Table 1. Participants involved in the study phases.
Phase

Patients

Exploration

A subset of patients with metastatic breast cancer referred Oncologists from 3 community hospitals and oncologists at
to Siteman Cancer Center (SCC) before the implementa- SCC (n=32)
tion phase (n=10)

Preparation

None recruited (patient advocate included as part of the
research team)

Implementation

Newly diagnosed (de novo) patients or patients with re- Same group as in the exploration phase
current disease referred to SCC after the exploration phase
(n=34)

Sustainment

Patients recruited in the implementation phase

Study Components
Project ADAPT has 5 intervention components designed to
enhance communication between providers, continue
engagement between research and clinical teams, and provide
optimal patient care regardless of geographic location. These
components are as follows: (1) ADAPT coordinator; (2) Epic
communication between providers and research teams; (3)
Powerful partnerships with collaborating sites; (4) WUSM
clinical trial finder; and (5) Virtual consult/telemedicine.

ADAPT Coordinator
The ADAPT coordinator is the facilitator and intermediary
between the NCI-designated SCC and our 3 community
hospitals within the NCORP. The ADAPT coordinator handles
all operations for the study to run smoothly. The ADAPT
https://www.researchprotocols.org/2022/7/e35736
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Providers

Same group as in the exploration phase (including research
team)

Same group as in the exploration phase

coordinator disseminates information to all sites and handles
recruitment procedures, survey distribution, and data collection.
The ADAPT coordinator also leads the strategy and standardizes
the coordination for Epic patient identification and utilization
of the clinical trial finder, as well as virtual consults between
providers/telemedicine for patients. Specific training, including
On Core training, Epic training, and research training, and a
background in medicine, public health, or a health-related field
to review clinical trial eligibility information may be beneficial
for this role.

Epic Communication Between Providers and Research
Teams
Hospitals in the United States are required to use an electronic
medical record (EMR) system to manage patient health
information [29,30]. Epic is a type of EMR system that enables
JMIR Res Protoc 2022 | vol. 11 | iss. 7 | e35736 | p. 5
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customization and versatility across various hospital settings.
The secure chat feature within Epic is the potential
communication tool intended for study team communication.
The use of streamlined Epic communication processes between
community and academic center physicians and research staff
is designed to improve patient and provider satisfaction, enable
efficient consultation, and enhance clinical outcomes. In this
adaptation, we aim to leverage existing technology to facilitate
communication between the referring sites and SCC. Thus, we
identified an electronic communication option, such as Epic,
since oncologists were currently using this software to manage
patients. When considering reproducing this method for sites
using different EMR software or when scaling up to other sites
with differing EMR software in the future, leveraging existing
electronic communication channels, like secure group email or
Microsoft Teams, may be worth exploring through acceptability
and feasibility measures prior to selecting a communication
channel.
This study relies on a uniform strategy for providers to obtain
consults on patients with MBC via a previsit virtual consult that
is tracked and readily available in the EMR (ie, Epic),
significantly improving patient care and coordinating
communication between providers. Thus, we have identified
community sites that use Epic to facilitate communication. This
process simplifies referrals and enhances information security,
as this communication does not occur over email or phone calls,
but instead through Epic.

Powerful Partnerships With Collaborating Sites
Partnerships with our 3 community hospitals offer access to a
care network with an electronic health record (Epic) and diverse
provider systems to study wide-ranging management of patients
with MBC. This care model is designed as a bidirectional
partnership since the community sites have access to NCORP
resources. We aim to connect patients from SCC to these
resources to enhance admission and enrollment in clinical trials
at both community sites and SCC. Also noteworthy is that these
3 partner sites serve rural patient populations with MBC and
are located across the St. Louis region, representing the breadth
of care settings within the area.

WUSM Clinical Trial Finder
The WUSM clinical trial finder is a website that displays
available clinical trials at WUSM and SCC. The WUSM clinical
trial finder allows the ADAPT coordinator to identify clinical
trials for which patients at partner sites may be eligible. The
ADAPT coordinator facilitates coordination and communication
with the treating oncologists and clinical team members to
develop a detailed treatment plan for the patient. In addition,
the ADAPT coordinator conducts virtual demonstrations and
training to teach community sites the best approaches to navigate
the website and clinical trial tree.

Virtual Consult/Telemedicine
The virtual health care feature of Project ADAPT consists of
virtual consults between providers and telemedicine for patients.
Virtual consults between providers at partner sites are designed
to discuss potential referrals and clinical cases through secure
Epic communication. These virtual meetings allow for
https://www.researchprotocols.org/2022/7/e35736
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discussion of patient matters and determination of clinical trial
availability and eligibility for patients between oncologists at
SCC and community partner sites. This digital strategy will
enhance care delivery and reduce patient burden by preventing
potentially unneeded in-person screening as traditionally carried
out.
The second virtual feature is telemedicine. While there are
multiple definitions of telemedicine, telemedicine generally
applies digital media/platforms to aid the clinical decision of
providers in the management of patients [31,32]. This strategy
is designed for patients to receive care remotely through various
virtual communication tools [33]. The emergence of COVID-19
has caused a large increase in telemedicine use throughout the
US health sector in cancer care and primary health services
[34,35]. Project ADAPT’s telemedicine component affords a
patient access to specialist care from SCC without the need for
an in-person visit. This approach covers patients who need care
but cannot travel to SCC. It can also reduce patient time and
financial burden if consultation can be provided virtually rather
than as traditional in-person visits, preventing unnecessary
in-person consultations.

Study Measures
Several surveys employed within this study explore patients’
and providers’ satisfaction with the referral process and are
grouped into patient and provider surveys. Surveys designed
for the patient population are as follows: (1) ADAPT patient
survey; (2) ADAPT patient sociodemographic survey; (3) Epic
data extraction form; and (4) Decision Regret Scale
[36] (Multimedia Appendices 1-5).
The ADAPT patient survey (Multimedia Appendix 1) captures
patients’ satisfaction and acceptability of the current referral
process. There are open-ended and free-response options that
offer participants the opportunity to provide insights and
experiences valuable to the study. The ADAPT patient
sociodemographic survey (Multimedia Appendices 2 and 3)
includes baseline characteristics of patients with MBC referred
from outside institutions to SCC to gain insights into the
backgrounds of our patient sample population. The Epic data
extraction form (Multimedia Appendix 4) gathers information
on tumor characteristics, treatment history, and receptor status
from Epic. The Decision Regret Scale [36] (Multimedia
Appendix 5) evaluates patients’ feelings of regret (if any)
regarding transferring cancer care from partner sites to SCC.
Surveys for the providers recruited into Project ADAPT are as
follows: (1) ADAPT provider survey and (2) Implementation
Climate Scale [37] (Multimedia Appendices 6-8). The ADAPT
provider survey (Multimedia Appendices 6 and 7) emphasizes
providers’ satisfaction and acceptability of the current referral
process, and the Implementation Climate Scale [37] (Multimedia
Appendix 8) captures the level of application of evidence-based
health practices at the partner sites. These surveys also include
free-response options that delve deeper into providers’
encounters with the referral system.
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Study Phases/Procedures
Exploration Phase: Gathering Information and
Recruitment
In the exploration phase, the ADAPT coordinator identifies
approximately 10 patients through Epic who have been
previously referred to SCC from external institutions (to the
breast oncologists at SCC involved in this study). These patients
are contacted via phone to inquire if they are willing to
participate in this phase of the study. If they agree to participate,
they consent during the phone call and complete the ADAPT
patient survey and sociodemographic questions through the
Research Electronic Data Capture (REDCap) link [38,39] sent
to their email addresses or over the telephone.
Oncologists at SCC and the partner sites are involved during
this study phase. The research team discusses the proposed
ADAPT process through virtual meetings and refines the
recruitment process from feedback during these meetings. These
virtual meetings facilitate continued buy-in and leadership from
referring providers to champion the intervention at their sites.
In addition, providers at partner sites and SCC are recruited by
email, provide consent, and then can complete the ADAPT
provider survey through REDCap links sent to their email
addresses.
The following privacy protections are enacted for all email
communications involving protected health information: (1)
emails are sent securely (ie, [secure] in the subject line); (2) the
body of the email instructs the participant to send all information
as a response to this thread and to not remove “[secure]” from
the subject line; and (3) the participant’s agreement to provide
information over email is documented in our research records.
Multimedia Appendix 9 outlines the recruitment processes of
the exploration phase in a flow diagram.

Preparation Phase: Procedures
Research subjects are not recruited during this phase. Data
collected during the exploration phase guide the preparation
phase strategies, including how the ADAPT coordinator leads
the process for facilitating the following: (1) patient
identification for the implementation phase; (2) WUSM central
clinical trial finder; and (3) virtual consult/telemedicine. There
is ongoing engagement with oncologists and the research team
at both SCC and community sites to incorporate modifications
as needed at this study phase, as illustrated in Figure 1.

Implementation Phase: Recruitment and Procedures
The recruitment process can be done in 2 ways. The partner site
clinical/research team members identify patients with MBC,
and they contact the ADAPT coordinator who screens the
patients with MBC for eligibility or the ADAPT coordinator
identifies an eligible patient at a partner site through granted
access to the Epic database through the following processes.
The partner site provides a list of participating providers’ clinic
schedules and hospital names on Epic. According to the
oncologists’ schedules, the ADAPT coordinator maps out
weekdays to screen providers’ lists of scheduled patients before
their appointment day in Epic. The ADAPT coordinator then
contacts the partner site provider (or the provider’s clinical
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team) scheduled to see the patient, alerting the provider of the
patient’s eligibility status and available ADAPT resources (eg,
ADAPT coordinator, clinical trial finder, and virtual
consultation/telemedicine). The clinical/research team members
at the partner site discuss the options with the patient. If
interested, the patient can provide consent to either the research
team at the partner site or a SCC site research coordinator
(including the ADAPT coordinator). The patient is treated at
SCC or declines (eg, declines participation or decides to be
treated at the referring facility). Patients can refuse to participate
and continue treatment at their preferred location.
These recruitment strategies are designed to accommodate our
partner sites’ different human and material resources to provide
a seamless recruitment process. Partner sites can either have
the ADAPT coordinator lead the recruitment process of
screening and identifying eligible participants through the
detailed process outlined above while the research team obtains
consent from the patients at the clinic through REDCap, or
decide to oversee the recruitment process as the best fit for their
respective centers and obtain consent from the patients at the
clinic through REDCap. There must be regular communication
between the ADAPT coordinator and the delegated recruitment
research staff at these centers to evaluate or modify these
processes if needed.
For those patients who provide consent, the ADAPT coordinator
collects acceptability and satisfaction surveys at enrollment and
at 3 and 6 months. During the implementation phase, providers
complete the ADAPT provider survey and the Implementation
Climate Scale [37] at baseline and at 3 and 6 months through
REDCap. The providers recruited from the 3 community
hospitals and at SCC in the exploration phase are the same
providers involved at this stage, so they would not need to
provide consent again. Multimedia Appendix 10 outlines the
flow of the recruitment process.

Sustainment Phase: Recruitment and Procedures
The acceptability and satisfaction surveys collected at enrollment
and at 3 and 6 months provide the feedback needed to adapt the
implementation strategy (Figure 1). Our conceptual framework
is a dynamic implementation approach to incorporate ongoing
feedback to inform ad hoc adaptation. Therefore, we can modify
the implementation strategy during our data collection process.
During the sustainment phase, the ADAPT coordinator will
complete adoption and fidelity observation measures to ensure
the sustainment of the intervention. In addition, modified
satisfaction and acceptability measures will be administered to
patients and providers to continue evaluating and adjusting the
program as needed.

Statistical Analysis
Quantitative Analysis
Only a subset of patients previously referred to SCC (n=10)
who complete surveys in the exploration phase will require
descriptive statistics for the measures completed.
The Epic data extraction form measures are collected at T0 and
T2 in the implementation phase. Specifically, clinical or
pathologic stage and the date of diagnosis of metastatic disease
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are collected at T0 only. Receptor status is collected at T0 for
all the enrolled patients and at T2 for patients with a subsequent
biopsy. The number of prior and current lines of therapy are

collected at T0 and T2 for all the enrolled patients. The measures
at T0 and T2 are shown in Table 2.

Table 2. Patient assessment tools/schedule.
Measures

Exploration (0-3

Preparation

months)a

Epic data extraction form

a

Yes

No

Implementation phaseb
T0

T1 (3 months)

T2 (6 months)

Yes

No

Yes
c

Yesc

Sociodemographic survey

Yes

No

Yes

Yes

ADAPTd patient survey

Yes

No

Yes

Yes

Yes

Decision Regret Scale [36]

No

No

No

Yes

Yes

Only a subset of patients previously referred to SCC (n=10) is consented to complete surveys before the implementation phase begins.

b

Patients enrolled in the implementation phase represent new patients referred from our partner sites to SCC for treatment.

c

We are capturing changes to already provided sociodemographic information from enrolled participants, such as changes in insurance provider status.

d

ADAPT: adapting and developing an academic and community practice collaborative care model for metastatic breast cancer care.

For other measures collected at multiple time points (eg,
sociodemographic questions), a generalized estimating equation
(GEE) model with appropriate link function is used to analyze
the longitudinal data. The correlation among the repeated
measures from the same participant needs to be considered. We
are using an autoregressive of the first order as a working
correlation structure, and patients with missing values at any
time points are excluded from the GEE analysis. The GEE model
includes time points. The GEE model’s P values from type 3
analysis are used to assess whether the outcomes across all time
points are different. The least-square means for each outcome
at each time point are then estimated. The standard errors are
calculated using the GEE sandwich method when accounting
for within-patient correlation. All analyses are conducted using
SAS (SAS Institute) at the 2-sided 5% significance level. To
prioritize improving satisfaction and acceptability across
educational groups, racial/ethnic groups, or diagnosis stage, a
subgroup analysis by race/ethnicity to identify any potential
similarities or differences in responses is conducted.

Qualitative Analysis
A minimum of 2 research team members will use conventional
content analysis to analyze responses from the open-ended and
free-response questions [40]. This approach is partially rooted
in naturalistic inquiry to explicate patient experiences and
perspectives [41]. Any discrepancies in the analysis will be
resolved through consensus coding. If the 2 coders cannot reach
a consensus, a third research team member will act as a
tiebreaker. Topics derived from the content analysis are used
to adapt and modify the implementation strategy. This
mixed-methods approach allows for a more in-depth and rich
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description of patient acceptability and satisfaction to provide
context to the quantitative data.

Sample Size Calculation
As this is a feasibility investigation, there is no pilot data. One
purpose of this study is to obtain measures of central tendency
and variability to inform power calculations for our future
randomized controlled trial. Sample size estimates are dependent
on the effect size, defined as the difference of T2 (6 months)
and T0 (enrollment) divided by the standard deviation. Using
a 2-tailed paired t test, 44 patients (including 10 patients from
the exploration phase) and 32 oncologists are required to detect
an effect size of 0.5 with 80% power at a level of significance
of .05.

Results
The lead site WUSM received single IRB approval in June 2021,
and data collection commenced immediately. As of August
2021, the research team has completed participant recruitment
for the exploration phase with 10 patients and 11 providers from
SCC, who completed surveys for the exploration phase, as
shown in Tables 2 and 3. The participating sites are still at
various stages of the single IRB approval process, which
involves a signed reliance agreement between institutions, site
registration, and a Project ADAPT application process. Once
approvals are granted, oncologists at these partner sites are to
complete surveys for the exploration and preparation phases to
be finalized, as outlined in Table 1. We have incorporated a
patient advocate into the study to understand patient cancer care
pathways for reaching and engaging with more patients at the
community level.
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Table 3. Provider assessment tools/schedule.

a

Preparationa

T0b

T1 (3 months)

T2 (6 months)

Siteman and community/partner Yes
site providers

No

Yes

Yes

Yes

Siteman and community/partner No
site providers

No

Yes

Yes

Yes

Measure

Providers involved

ADAPTc provider survey
Implementation Climate
Scale [37]

Exploration

No survey is administered during the preparation phase.

b

The implementation phase starts at T0, marking the enrollment of patient participants to the study, and ends at T2.

c

ADAPT: adapting and developing an academic and community practice collaborative care model for metastatic breast cancer care.

Discussion
Overview
Our adapted coordinated care model can enhance relationships
among academic and community cancer centers. This model
has the potential to improve patient and provider satisfaction
and acceptability of the cancer care referral process. We
anticipate that patients and providers can help identify
limitations with the current MBC referral process to help identify
opportunities to improve satisfaction and acceptability. Through
Project ADAPT, we aim to positively impact clinical trial
enrollment for patients with MBC, improve case discussion
among providers, and provide a feasible and sustainable solution
for improving care among patients with MBC. Moreover, as
the number of women living with MBC continues to grow, our
research extends beyond existing advancements in treatment
[20,42] to evaluate interventions that have the potential to
improve quality of life. We plan to disseminate our findings
through academic platforms (eg, conferences and peer-reviewed
journal articles), and we plan to make our data publicly available
while adhering to IRB protocols. In addition, we will
disseminate our findings to our community partner sites in a
consumer-friendly plain language format.
There are few studies on the impact of collaborations among
different hospitals to improve MBC care coordination. Only
the EMBRACE program, to our knowledge, has conducted a
multilevel systemic care coordination model for patients with
metastatic breast cancer. WUSM received IRB approval in June
2021 and has completed participant recruitment for the
exploration phase. WUSM has recruited 21 participants,
including patients and providers. The latest community hospital,
DDCI, joined the project in March 2021, while MBMC and
SIH onboarded in late 2020. All partner sites are going through
the single IRB registration in accordance with the current single
IRB policy of the National Institutes of Health for multisite
nonexempt human research carried out in the United States.
The aim is to enhance and standardize the IRB review process
among multiple research centers, avoiding duplication of review
efforts to allow research to begin promptly [43]. This single
IRB infrastructure has the potential to enhance the sustainability
of these research partnerships and collaborations.
All communication requires reaching out to key stakeholders
at these partner hospitals, presenting our research idea, and
requesting collaboration virtually via Zoom meetings. Continued
partnership and engagement have remained this way with a
digital media platform by scheduling regular monthly meetings
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with all team members via Zoom to discuss updates on the study,
recruitment and planning strategies, and IRB approval status.
The research team meets at a time when most, if not all, can
attend, and the ADAPT coordinator later sends out meeting
minutes to all members of the group via email. During the
research team meetings, study process modifications include
creating study materials, such as the ADAPT patient flier for
distribution to eligible patients at clinics and a page summary
of Project ADAPT for providers.
We are approved to conduct virtual consultation for providers
to share resources and knowledge among SCC, an
NCI-designated cancer center, and our partner sites with NCORP
clinical trial resources, creating a bidirectional relationship that
improves patient care. This virtual consultation runs
concurrently with telemedicine for patients. This platform of
providing care to patients with MBC has become even more
critical with the current COVID-19 pandemic [35]. This virtual
experience also captures patients who would not be able to travel
to SCC for whatever reason, but could still receive quality
specialist care through this medium.
Patient recruitment for the exploration phase is via telephone
calls, and surveys are distributed electronically through REDCap
links. Utilizing e-consent for Project ADAPT has made
recruitment manageable, especially during the COVID-19
pandemic. It resonates with studies showing that this approach
can enhance access to participation among rural cancer patients
in clinical trials, which is usually difficult due to geographic
location [19,44]. Moreover, through virtual demonstrations via
Zoom, the ADAPT coordinator has shown partner sites how to
navigate the clinical trial tree finder.
Use of the digital EMR Epic messaging tool for communication
among providers streamlines the referral process and allows
providers access to real-time information regarding available
clinical trials at SCC. Finally, as we prepare for the
implementation phase, we strive to improve this design model
with input from experts in different fields participating in the
study and lessons learned from each stage of this study.

Limitations
We have buy-in and support from the leadership, oncology
teams, and staff at the community partner sites. A minimum
commitment of monthly scheduled communication throughout
the duration of the project is expected, and continued
engagement in the adaptation process will be needed from all
sites. It is possible that the initial support and enthusiasm for
this project will diminish, but we are using an
JMIR Res Protoc 2022 | vol. 11 | iss. 7 | e35736 | p. 9
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implementation-science framework to enhance continued
engagement. In addition, we are working with sites that use the
Epic EMR system. The feasibility data collected in this
investigation will give us a sense of the timeline, personnel, and
community setting infrastructure, including the EMR system,
needed for scaling up this type of study.

Opportunities for Future Research
WUSM research team members have launched a single IRB
Support Network to develop a shared repository of resources
and information to help guide partner sites through the single
IRB process. We are in the process of creating a toolkit of
resources to illustrate, in plain language, the single IRB
application process. This toolkit will create a shared database
with information about existing single IRB relationships with
external partners (eg, key characteristics about the site and the
research infrastructure, existing IRB agreements with WUSM,
and past/current studies collaborated on with WUSM) and help
to determine outreach strategies that best support partner sites
throughout the single IRB process. For example, the study team

Housten et al
has found that smaller community sites often lack third-party
accreditations for their clinical research programs that may be
more commonplace for larger academic health centers. In this
way, the single IRB application process for studies that include
a wide variety of recruitment sites would benefit from a
streamlined approach to ensure the protection of human research
subjects while accommodating the unique capabilities of each
site.
In preparation for a larger trial, our team will complete
provider-focused Pragmatic Explanatory Continuum Indicator
Summary-2 (PRECIS-2) [45]. Evaluating our approach using
the 9 PRECIS-2 domains (ie, eligibility, recruitment, setting,
implementation resources, provider strategy flexibility,
intervention flexibility, data collection, primary outcome, and
primary analysis) will facilitate engagement from our care
coordination stakeholders to match our research approach with
the overall study aims of a future trial. The implementation
science methods used throughout Project ADAPT will establish
a robust methodological foundation for future trials investigating
care coordination across multiple sites.
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